AILERON THERAPEUTICS INC: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei AILERON THERAPEUTICS INC listata cu simbolul US.ALRN ==Descriere companie== Aileron Therapeutics, Inc. (www.aileronrx.com) is a clinical-stage chemoprotection oncology company. The Company is focused on transforming the experience of chemotherapy for cancer patients. It is developing ALRN-6924, which is their dual Mouse double minute 2 homolog (MDM2) and MDMX inhibitor to provide a single medicine to protect multiple healthy cell types throughout th...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Aileron Therapeutics, Inc. (www.aileronrx.com) is a clinical-stage chemoprotection oncology company. The Company is focused on transforming the experience of chemotherapy for cancer patients. It is developing ALRN-6924, which is their dual Mouse double minute 2 homolog (MDM2) and MDMX inhibitor to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells. ALRN-6924 acts as an agent to reduce the toxic side effects of chemotherapy in the bone marrow of cancer patients without adversely impacting the anti-cancer activity of chemotherapy against p53-mutant tumors. | [[Aileron Therapeutics]], Inc. (www.aileronrx.com) is a clinical-stage chemoprotection oncology company. The Company is focused on transforming the experience of chemotherapy for cancer patients. It is developing ALRN-6924, which is their dual Mouse double minute 2 homolog (MDM2) and MDMX inhibitor to provide a single medicine to [[PROTECT|protect]] multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells. ALRN-6924 acts as an agent to reduce the toxic side effects of chemotherapy in the bone marrow of cancer patients without adversely impacting the anti-cancer activity of chemotherapy against p53-mutant tumors. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||